Therapeutic drug monitoring practice in patients with active tuberculosis: assessment of opportunities

Eur Respir J. 2021 Jan 28;57(1):2002349. doi: 10.1183/13993003.02349-2020. Print 2021 Jan.

Authors

Hannah Yejin Kim^{1

2

3}, Evan Ulbricht⁴, Yu Kyung Ahn¹, Isabelle Sarah Gillooly¹, Kher Jing Lee¹, Jessica Lieu¹, William Nguyen¹, Sylvia Young¹, Jin-Gun Cho^{4

5

6}, Jan-Willem Alffenaar^{1

2

3}

Affiliations

¹ Sydney Pharmacy School, Faculty of Medicine and Health, The University of Sydney, Camperdown, Australia.
² Clinical Pharmacy, Westmead Hospital, Westmead, Australia.
³ Marie Bashir Institute for Infectious Diseases and Biosecurity, The University of Sydney, Camperdown, Australia.
⁴ Parramatta Chest Clinic, Parramatta, Australia.
⁵ Dept of Respiratory and Sleep Medicine, Westmead Hospital, Westmead, Australia.
⁶ Sydney Medical School, Faculty of Medicine and Health, The University of Sydney, Camperdown, Australia.

PMID: 32817005
DOI: 10.1183/13993003.02349-2020

No abstract available

Publication types

Letter

MeSH terms

Antitubercular Agents / therapeutic use
Drug Monitoring*
Humans
Tuberculosis* / drug therapy

Substances

Antitubercular Agents